Morgan Stanley Resumes Abbvie (ABBV) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Pharmacyclics (ABBV) Initiatives IMBRUVICA Combo Phase Ib/II (AZN)
May 28, 2015 9:01 AM EDTAbbVie's (NYSE: ABBV) Pharmacyclics, Inc. announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca (NYE: AZN). The Phase Ib/II study will examine the safety, tolerability and effectiveness of this... More
AbbVie (ABBV) Announces Completion of Pharmacyclics Acquisition
May 26, 2015 8:33 AM EDTAbbVie (NYSE: ABBV) has completed the acquisition of Pharmacyclics, Inc. (Nasdaq: PCYC) enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a leader in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 billion global market.
"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.... More
